此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

An Open-Label Food Effect Study of Telotristat Etiprate

2014年9月5日 更新者:Lexicon Pharmaceuticals

A Phase 1, Randomized, Single Center, Open Label, 2 Sequence, 2 Period, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of Telotristat Etiprate (LX1606 Hippurate) in Healthy Male and Female Subjects

This study is designed to evaluate the effect of food on the pharmacokinetics (PK) of telotristat ethyl and its metabolite LP-778902 relative to administration of single dose telotristat etiprate in the fasted state in healthy adult male and female subjects.

研究概览

研究类型

介入性

注册 (实际的)

22

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Wisconsin
      • Madison、Wisconsin、美国、53704
        • Lexicon Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Healthy adult subjects aged ≥18 to ≤55 years of age at screening
  • Body mass index ≥18.0 to ≤32.0 kg/m^2
  • Acceptable vital signs at Screening: Systolic blood pressure = 90-140 mm Hg, Diastolic blood pressure = 50-90 mm Hg, Heart rate = 40-100 beats per minute
  • Able and willing to ingest an entire high fat/high caloric breakfast meal within 30 minutes
  • Willingness to adhere to the restrictions outlined in the protocol
  • Able to comprehend and sign the Informed Consent Form

Exclusion Criteria:

  • Presence of any clinically significant physical, laboratory, or ECG finding that may interfere with the study in the opinion of the Investigator
  • Use of any medications, herbal tea, energy drink, herbal products, or supplements within 14 days of study start
  • Receipt of any investigational agent or study drug within 30 days or 5 half-lives prior to Screening
  • Receipt of any protein- or antibody-based therapeutic agent within 3 months prior to Screening
  • Prior exposure to telotristat etiprate
  • Use of tobacco, smoking cessation products, or nicotine products within 3 months prior to Screening
  • History of major surgery within 6 months prior to Screening
  • History of any GI surgery that may induce malabsorption
  • History of renal disease, or significantly abnormal glomerular filtration rate (<90 mL/min as calculated using the Cockcroft-Gault equation) at Screening
  • History of hepatic disease, or significantly abnormal liver function tests at Screening
  • History of any clinically significant psychiatric, renal, hepatic, pancreatic, cardiovascular, neurological, endocrinologic, hematological, or GI abnormality
  • History of any active infection within 14 days prior to Screening
  • History of alcohol or substance abuse within 2 years prior to Screening
  • Positive hepatitis panel (including hepatitis B surface antigen and hepatitis C virus antibody) or positive human immunodeficiency virus antibody screens
  • Concurrent conditions that could interfere with safety and/or tolerability measurements
  • Donation or loss of >500 mL of blood or blood product within 3 months prior to Screening
  • Women who are breastfeeding or are planning to become pregnant during the study
  • Positive serum pregnancy test (females only)
  • Positive urine screen for selected drugs of abuse and cotinine
  • Consumption of alcohol within 48 hours prior to study start
  • Consumption of caffeine- and/or xanthine-containing products within 72 hours of study start
  • Consumption of grapefruit, Seville oranges, and grapefruit- or Seville orange-containing products within 72 hours prior to study start
  • Unable or unwilling to communicate or cooperate with the Investigator for any reason

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment A
Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fed condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fasted condition.
2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
实验性的:Treatment B
Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fasted condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fed condition.
2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Telotristat ethyl 的血浆浓度
大体时间:第 1、2、3、6、7、8 天
第 1、2、3、6、7、8 天
Plasma concentration of metabolite LP-778902
大体时间:Days 1, 2, 3, 6, 7, 8
Days 1, 2, 3, 6, 7, 8

次要结果测量

结果测量
大体时间
Number of treatment emergent adverse events
大体时间:10 days
10 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年6月1日

初级完成 (实际的)

2014年7月1日

研究注册日期

首次提交

2014年6月4日

首先提交符合 QC 标准的

2014年6月5日

首次发布 (估计)

2014年6月6日

研究记录更新

最后更新发布 (估计)

2014年9月8日

上次提交的符合 QC 标准的更新

2014年9月5日

最后验证

2014年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • LX1606.1-107-NRM
  • LX1606.107 (其他标识符:Lexicon Pharmaceuticals, Inc.)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅